Biotech Values

[dangerM]

Well, this belongs to one of the open questions:

#ESMO17 PACIFIC Discussion with possible mechanisms behind why radiotherapy and Immunotherapy can be excellent partners pic.twitter.com/jVFWxMU0tS

— Ajaz B. (@ajazbulbul) September 9, 2017

Following these hypotheses it'd make sense to shorten the time lag between radio(chemo)therapy and checkpoint inhibitor. However, IMHO this still should be a sequential therapy (i.e. checkpoint inhibitor in an adjuvant setting). If really concurrent, I'm sceptical how much time the pauses within the radiation schedule give for the immune system to act.

> My question regarding PACIFIC is whether it might be more efficacious to treat Stage III NSCLC with simultaneous chemo/radiation/Imfinzi

Yes. We will see these kind of studies. Obviously stage III has been receiving not enough attention and is too "under/unstudied" from IO/checkpoint inhibitor perspective.